No benefit from addition of aliskiren to 'gold standard' ACE inhibitor

In one of the largest trials ever conducted in patients who have heart failure with reduced ejection fraction -- a measure of the heart's ability to pump blood -- the investigational drug aliskiren failed to show superiority over full-dose treatment with the existing 'gold standard' therapy, the angiotensin-converting enzyme inhibitor enalapril, researchers reported.
Source: ScienceDaily Headlines - Category: Science Source Type: news

Related Links:

Objective: To assess the prognostic value of electrocardiographic atrial fibrillation in older hypertensive people in the randomized, placebo-controlled Hypertension in the Very Elderly Trial. Methods: Hypertension in the Very Elderly Trial randomized 3845 hypertensive people aged 80 years and over, 3273 with electrographic data on the presence or absence of atrial fibrillation at baseline and without established cardiovascular disease. Multivariate Cox proportional hazard models were used to estimate hazard ratios with 95% confidence intervals (CIs) for all-cause mortality, incident fatal and nonfatal major cardiovas...
Source: Journal of Hypertension - Category: Cardiology Tags: ORIGINAL PAPERS: Risk factors Source Type: research
Based on reports from China, we know that most COVID-19 patients (about 80%) will develop mild flulike symptoms, including fever, dry cough, and body aches that can be managed at home. 20% will develop more serious symptoms, such as pneumonia requiring hospitalization, with about a quarter of these requiring ICU-level care. Initial reports focused on the respiratory effects of COVID-19, such as pneumonia and difficulty breathing. But more recent literature has described serious cardiovascular complications occurring in about 10% to 20% of hospitalized patients. Someone with pre-existing heart disease who becomes ill with C...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Health Heart Health Hypertension and Stroke Infectious diseases Source Type: blogs
Condition:   Acute Heart Failure Intervention:   Drug: Tolvaptan 15 MG Sponsors:   Gia Dinh People Hospital;   Otsuka Pharmaceutical Vietnam Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Chronic Heart Failure Intervention:   Other: Exercise with and without Codeine Sponsor:   University of Leeds Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Acute Heart Failure Intervention:   Drug: Tolvaptan 15 MG Sponsors:   Gia Dinh People Hospital;   Otsuka Pharmaceutical Vietnam Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Chronic Heart Failure Intervention:   Other: Exercise with and without Codeine Sponsor:   University of Leeds Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Ishida Y, Murayama H, Shinfuku Y, Taniguchi T, Sasajima T, Oyama N Abstract Objectives: The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin is indicated for type 2 diabetes mellitus (T2DM). However, the long-term safety, effectiveness, and clinical relationship with cardiovascular events of vildagliptin have not been evaluated in Japan.Methods: The authors conducted post-marketing surveillance (PMS) to evaluate the safety and effectiveness of vildagliptin in more than 3000 Japanese T2DM patients for up to 3 years. Main assessments included demographics, major adverse cardiovascular events (MACE)...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
This article will review the epidemiology of heart failure in ESRD, the pathophysiological derangements of the renin–angiotensin–aldosterone system in patients with kidney disease, and the results from case series and trials of the use of MRAs in ESRD with HFrEF. Although limited to several small trials using MRAs in peritoneal and hemodialysis patients with or without HFrEF, the current literature appears to show the potential for clinical benefits with little risk.
Source: Cardiology in Review - Category: Cardiology Tags: Review Articles Source Type: research
Diabetes mellitus (DM) and chronic kidney disease (CKD) significantly increase the risk of cardiovascular morbidity and mortality. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a new class of hypoglycemic agents that have shown significant promise in the reduction of cardiovascular events. Current guideline recommendations do not support the use of these agents in patients with CKD stage 3 or higher. We performed a comprehensive meta-analysis to evaluate their cardiovascular effects in patients with type 2 DM and CKD stage 3 or higher. A comprehensive search was performed in PubMed, Cochrane central, and Embase. S...
Source: Cardiology in Review - Category: Cardiology Tags: Review Articles Source Type: research
Left ventricular noncompaction cardiomyopathy is a heart disease with relevant potential complications including heart failure, life-threatening arrhythmias, and embolic events. In order to prevent adverse outcomes, it is crucial to appropriately recognize and manage this cardiomyopathy. In this paper, we report the main clinical presentations and imaging modalities used for diagnosis, including echocardiography and magnetic resonance imaging. We highlight the role of a comprehensive functional cardiac evaluation and the possible prognostic implications of both systolic and diastolic dysfunction. Furthermore, we summarize ...
Source: Cardiology in Review - Category: Cardiology Tags: Review Articles Source Type: research
More News: Cardiology | Enalapril | Heart | Heart Failure | Science | Tekturna